Allogene Therapeutics (ALLO) Asset Utilization Ratio (2021 - 2026)
Allogene Therapeutics (ALLO) posted Asset Utilization Ratio of 0.0 for Q4 2024, down 44.42% sequentially from 0.0 in Q3 2024, and down 72.4% YoY from 0.0 in Q1 2024.
Allogene Therapeutics (ALLO) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
Allogene Therapeutics has reported Asset Utilization Ratio for 4 years, with the latest figure at 0.0 in Q4 2024.
- Quarterly Asset Utilization Ratio fell 72.4% year-over-year to 0.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.0 (down 72.4% YoY) and the FY2024 annual result came in at 0.0, down 71.54% from the prior year.
- Asset Utilization Ratio retreated to 0.0 in Q4 2024 per ALLO's latest filing, from 0.0 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.11 in Q4 2021 and troughed at 0.0 in Q4 2024.
- A 4-year average of 0.03 and a median of 0.0 in 2023 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2022 and 2023: Asset Utilization Ratio soared 135.45% in 2022, then slumped 99.84% in 2023.
- Over 4 years, Asset Utilization Ratio stood at 0.11 in 2021, then sank by 99.83% to 0.0 in 2022, then slipped by 22.95% to 0.0 in 2023, then slumped by 72.4% to 0.0 in 2024.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.0, 0.0, and 0.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | 0.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.01 |
| Dec 31, 2024 | 0.00 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.00 |
| Jun 30, 2023 | 0.00 |
| Mar 31, 2023 | 0.00 |
| Dec 31, 2022 | 0.00 |
| Sep 30, 2022 | 0.08 |
| Jun 30, 2022 | 0.08 |
| Mar 31, 2022 | 0.07 |
| Dec 31, 2021 | 0.11 |
| Sep 30, 2021 | 0.03 |
| Jun 30, 2021 | 0.03 |
| Mar 31, 2021 | 0.03 |